Why Cytokinetics (CYTK) Shares Are Trading Higher Today?

Cytokinetics Incorporated CYTK shares continue to move forward after it announced positive REDWOOD-HCM Phase 2 data for CK-274 and garnered favorable comments from analysts.

  • On Tuesday, Barclays raised Cytokinetics price target to $40 from $28, equivalent to an upside of around 30%, and kept an Overweight rating. 
  • Analyst Carter Gould views yesterday's data as "highly favorably" and sees them as both de-risking and differentiating on efficacy" versus MyoKardia's mavacamten.
  • Cantor Fitzgerald also raised the target price to $48 from $35, with an Overweight rating unchanged. 
  • Analyst Charles Duncan has enhanced conviction in CK-274, resulting from positive Phase 2 data.
  • Monday afternoon, the Company announced equity raise of $200 million to support the Phase 3 clinical trial of CK-274.
  • See the offering prospectus here.
  • Price Action: CYTK Shares are up 8.35% at $29.26 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CareFinancingPrice TargetOfferingsAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!